[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-syndrome":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,52,86,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100475904","phase-3-evaluation-of-low-dose-colchicine-and-ticagrelor-in-prevention-of-ischemic-stroke-in-patients-with-stroke-due-to-atherosclerosis-100475904",false,"NCT05476991","Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis","Reducing Inflammation in Ischemic Stroke With Colchicine, and Ticagrelor in High-risk Patients-extended Treatment in Ischemic Stroke","RIISC-THETIS","Inclusion criteria:\n\nPatient should have the following:\n\nPatient with:\n\n1. Cerebral infarction (CI) proven by neuro-imaging (MRI or head-CT), immediately once the neurologic deficit is stabilized (investigator judgement) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event (TIA with documented ischemic lesion (MRI or CT) in the appropriate area corresponding to the symptoms will be considered CI, following the current definition)\n2. Or TIA lasting more 10 minutes or more (with motor symptoms or aphasia\u002Fdysarthria or visual defect), with total resolution and no brain lesion on neuro-imaging (TIA) and with ipsilateral carotid stenosis that was revascularized (endarterectomy or stenting) or with ipsilateral, potentially causal intracranial stenosis ≥70%) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event\n3. and documented atherosclerotic stenosis:\n\n   1. presence of carotid atherosclerotic stenosis (on the basis of carotid duplex, CTA, MRA, XRA - only the report will be required to document atherosclerotic disease) ipsilateral to the cerebral ischemic symptoms (stenosis defined by luminal narrowing ≥30%, judgement of the investigator)\n   2. or presence of atherosclerotic stenosis of another cerebral artery (documented vertebral artery stenosis, basilar artery stenosis, other intracranial artery stenosis) ipsilateral to the ischemic area (stenosis defined by luminal narrowing ≥30%, judgement of the investigator)\n   3. or presence of atherosclerotic disease of the aortic arch with a plaque ≥4mm in thickness with or without superimposed thrombus, or a plaque \\\u003C4 mm with a superimposed mobile thrombus (detected by transesophageal echocardiography or CT angiography)\n4. with no clear indication of colchicine treatment (gout, Mediterranean fever) and with an indication to long-term antiplatelet therapy (no clear indication to oral anticoagulant)\n5. age equal or above 18\n6. Rankin score less than ≤4 (ranges from 0 to 6, with 0 indicating no symptoms, 1 no disability, 2 to 3 needing some help with daily activities, 4 to 5 dependent or bedridden, and 6 death),\n7. fully informed and signed inform consent\n8. with social security number.\n9. medical examination before the participation to the research\n10. Under contraception in case of childbearing potential (highly effective: 1) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation et 2) progestogen-only).\n11. Pregnancy test for women of childbearing potential\n\nExclusion Criteria:\n\n1. Colchicine treatment needed (e.g., gout, Mediterranean fever)\n2. Hypersensitivity to ticagrelor or any of the excipients.\n3. Hypersensitivity to colchicine or any of the excipients.\n4. Major digestive disorders (chronic diarrhea, inflammatory disease of the digestive tract as uncontrolled ulcerative colitis or active Crohn disease)\n5. Immunosuppression, medullary aplasia\n6. Active chronic inflammatory disease, chronic active infection, evolving cancer\n7. Hemodynamic instability (need for amines for more than 24 hours, circulatory assistance)\n8. A recent severe sepsis (7 days) or all recent acute reaches\n9. Chronic treatment (for more than 6 months) with corticosteroids or NSAIDs (or repeated high-dose intake for less than 7 days).\n10. Anticipated concomitant oral or intravenous therapy with strong CYP3A4 inhibitors or CYP3A4 substrates than cannot be stopped for the course of the course of this study\n11. CI\u002FTIA due to arterial dissection (as documented following the judgment of the investigator) or due to cardiac source of embolism without documented atherosclerotic disease (e.g., mitral stenosis or endomyocardial fibrosis, endocarditis) a patient with atrial fibrillation, or with a history of myocardial infarction, or with calcified aortic stenosis will be eligible if the above inclusion criteria are also met\\]\n12. Indication to long-term oral anticoagulant treatment (e.g., atrial fibrillation)\n13. Symptomatic hemorrhagic stroke (the mere presence of asymptomatic cerebral hemosiderin deposits -so called \"microbleedings\" - on gradient echo imaging is not an exclusion criteria)\n14. Active pathological bleeding\n15. Uncontrolled hypertension (investigator judgement)\n16. Follow-up visit impossible or anticipated bad compliance.\n17. Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits..\n18. Anticipated pregnancy at time of enrollment in the study\n19. Breastfeeding woman\n20. Patients participating in another pharmaco therapeutic program with an experimental therapy that is known to affect the ticagrerlor, colchicine or aspirine therapy.\n21. Leukopenia \\\u003C3000\u002Fμl\n22. Patients with severe renal impairment (creatinine clearance \\\u003C 30 ml\u002Fmin)\n23. Patients with severe hepatic impairment\n24. Prohibited treatments: All treatments contraindicated during the use of colchicine and\u002For ticagrelor","ALL","18 Years",{"count":20,"type":21},2800,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","REDUCING INFLAMMATION IN ISCHEMIC STROKE WITH COLCHICINE, AND TICAGRELOR IN HIGH-RISK PATIENTS-EXTENDED TREATMENT IN ISCHEMIC STROKE.",[27,28,29,30,31,32,33,34],"Stroke","Stroke, Ischemic","Atherosclerosis","Myocardial Infarction","Coronary Syndrome","TIA","Cardiac Disease","Cerebral Infarction",[27,36,29,37,38],"Colchicine","Aspirin","Ticagrelor","RECRUITING","2025-09-01",{"date":42,"type":43},"2025-09-08","ACTUAL",{"date":45,"type":43},"2023-05-17",{"date":47,"type":21},"2027-09-01",{"name":49,"class":50},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":60,"enrollmentInfo":61,"targetDuration":63,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":74,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100559566","a-maajor-radiation-based-pci-study-in-stemi-and-nstemi-100559566","NCT06565793","A MAajor RAdiation-based PCI Study in STEMI and NSTEMI","The Impact of Radiation Delivered to the Patient and the Amount of Iodinated Contrast Medium Injected in Complex Versus Noncomplex Percutaneous Coronary Intervention.","MARAA","Inclusion Criteria:\n\n* The patient presents with a STEMI or NSTEMI requiring either a non-complex or complex PCI.\n\nExclusion Criteria:\n\n\\-","90 Years",{"count":62,"type":21},15630,"5 Years","OBSERVATIONAL","In France and Italy, approximately 240,000 percutaneous coronary angioplasties (PCI) are performed annually, with an increasing number of complex procedures, including those involving the left coronary common trunk, a bifurcation, chronic occlusion, or requiring Rotablator Rotary Atherectomy (ARota). The medical literature lacks sufficient data regarding several key aspects of complex angioplasty. These include the epidemiological characteristics of patients undergoing such procedures, the impact of irradiation delivered and the quantity of iodine injected on these lengthy procedures, their procedural complication rate, and in-hospital mortality.",[67,68,69,70,71,72,31,73],"Myocardial Infarction (MI)","Radiation Toxicity","Coronary Stenosis","Coronary Thrombosis","Coronary Artery Calcification","Coronary Occlusion","Coronary Artery Disease",[75],"PCI,DES, Radiation","NOT_YET_RECRUITING","2024-12-21",{"date":79,"type":43},"2024-12-27",{"date":81,"type":21},"2025-03-01",{"date":83,"type":21},"2025-12-31",{"name":85,"class":50},"Centre Cardiologique du Nord",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":51},"100559260","body-composition-estimated-by-bioelectrical-impedance-analysis-in-patients-with-acute-coronary-syndrome-100559260","NCT06561815","Body Composition Estimated by Bioelectrical Impedance Analysis in Patients with Acute Coronary Syndrome.","Inclusion Criteria: All patients hospitalized in the Cardiovascular Care Unit with a diagnosis of acute coronary syndrome.\n\nExclusion Criteria: Decline to participate.",{"count":93,"type":21},100,"This study addresses the critical issue of obesity and its impact on patients with acute coronary syndrome (ACS). While obesity is a known risk factor for cardiovascular diseases, emerging evidence suggests that obese patients with coronary artery disease may have better survival outcomes-a phenomenon known as the \\"obesity paradox.\\"\n\nOur research aims to explore this paradox by examining the body composition of ACS patients using bioimpedance analysis (BIA). We will evaluate parameters such as lean mass, body fat, and fluid volume to assess their relationship with clinical outcomes, including mortality and the incidence of heart and kidney failure.\n\nBy focusing on body composition rather than just BMI, this study seeks to provide a more accurate understanding of how these factors influence patient outcomes. Conducted at a major hospital in Argentina, the study will contribute valuable insights into the role of body composition in the prognosis of ACS, potentially informing more personalized treatment strategies.",[31,96],"Obesity",[98,99,100],"Obesity Paradox","Acute Coronary Syndrome","Body Composition","2024-08-15",{"date":103,"type":43},"2024-08-20",{"date":105,"type":43},"2023-02-11",{"date":107,"type":21},"2025-11-30",{"name":109,"class":50},"Hospital de Clinicas José de San Martín",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":51},"100520562","rna-as-prognostic-biomarkers-in-patients-with-acute-coronary-syndrome-100520562","NCT06058182","RNA as Prognostic Biomarkers in Patients With Acute Coronary Syndrome","RNAacs","Inclusion Criteria:\n\n1. Age \\>18 years\n2. Patients with ACS (first episode), defined according to the guidelines of the European Society of Cardiology (ESC) 2017\n3. Indication for percutaneous revascularization treatment\n4. Informed consent to study enrollment\n\nExclusion Criteria:\n\n1. Severe valve disease or other conditions requiring cardiac surgery\n2. Previous cardiac surgery including coronary artery bypass grafts\n3. Total chronic occlusions\n4. Patients with known hypersensitivity or contraindication to any of the following drugs:\n\n   * heparin\n   * aspirin,\n   * clopidogrel,\n   * ticlopidine,\n   * sirolimus,\n   * everolimus.\n5. Any contraindication to drug-eluting stent implantation (DES)\n6. Patients with a documented history of myocardial infarction;\n7. Left ventricular ejection fraction (LVEF) \\\u003C30% before PCI\n8. Patients in cardiogenic shock\n9. Patients with advanced ST-segment elevation myocardial infarction (\\> 48 h from onset of symptoms\u002FQ waves on electrocardiogram) or undergoing fibrinolysis;\n10. Patients with prior known cardiomyopathy with LVEF \\\u003C 40%\n11. Patients with malignant neoplasm or systemic disease with quoad vitam prognosis less than 1 year;\n12. Patients with known active infectious diseases;\n13. Patients who are unable to express valid informed consent to the act of enlistment\n14. Pregnant women",{"count":118,"type":21},70,"Identify circulating protein-coding (mRNAs) or non-coding (ncRNAs) transcripts (ACS\\_signature) predictive of ventricular dysfunction in ACS patients undergoing PCI.",[31],"2023-10-04",{"date":123,"type":43},"2023-10-06",{"date":125,"type":43},"2020-07-13",{"date":127,"type":21},"2027-01-30",{"name":129,"class":50},"IRCCS Policlinico S. Donato"]